-

06:36:30 AM

IMTX Stock News

IMTX - Immatics N.V

05/18/22 7:00 AM

Nasdaq : IMTX

Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1, a PD-1 immune checkpoint inhibitor, in patients with multiple solid tumors Initiation of the combination treatment follows

RHEA-AI

neutral

05/10/22 7:00 AM

Nasdaq : IMTX

clinical trial

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Patient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors TCER® IMA401 targets MAGEA4/8 and will be developed in

RHEA-AI

very positive

03/23/22 7:00 AM

Nasdaq : IMTX

earnings

Immatics Announces Full Year 2021 Financial Results and Corporate Update

IMA203 TCR-T candidate targeting PRAME demonstrated a 50 % objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation M ultiple IMA203 Ph ase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level , checkpoint

RHEA-AI

neutral

02/04/22 6:59 AM

NYSE, Nasdaq : BMY, IPSC, IMTX

earnings

ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

Bristol Myers Squibb today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’ s pipeline that further progressed the company’ s portfolio renewal. “I am proud of how our company performed in 2021, helping more patients across our...

RHEA-AI

neutral

02/04/22 6:59 AM

NYSE, Nasdaq : BMY, IPSC, IMTX

earnings

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

Bristol Myers Squibb today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’ s pipeline that further progressed the company’ s portfolio renewal. “I am proud of how our company performed in 2021, helping more patients across our...

RHEA-AI

neutral

12/14/21 6:59 AM

NYSE, Nasdaq : BMY, IMTX

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net...

RHEA-AI

positive

12/14/21 6:59 AM

Nasdaq : IMTX

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770

RHEA-AI

positive

11/16/21 7:00 AM

Nasdaq : IMTX

earnings

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

Interim data update at SITC for ongoing ACTe ngine ® IMA203 trial targeting PRAME demonstrated clinical responses a cross multiple solid tumor types during dose escalation phase Immatics to i nitiate three expansion cohorts for IMA203 targeting PRAME : monotherapy, combination with checkpoint

RHEA-AI

neutral

11/09/21 8:00 AM

Nasdaq : IMTX

clinical trial

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancer

RHEA-AI

neutral

11/01/21 8:00 AM

Nasdaq : IMTX

conferences

Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its

RHEA-AI

neutral

IMTX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websiteimmatics.com
Security nameImmatics N.V
Issue typecs
SectorManufacturing
Sic code2836
Employees2021
Tags
- Health Technology
- Biotechnology
AddressPaul Ehrlich-Strasse 15
StateBaden Wuerttemberg
CityTuebingen
Zip72076
CountryGermany
Phone4970715397700

About Immatics N.V

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.